Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 10/20 | 0.58 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.58 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.58 |
| ▸ | EDNRB | P24530 | 2/20 | 0.38 |
| ▸ | EDNRA | P25101 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HTR6 | P50406 | 1/20 | 0.37 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.37 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
| ▸ | F10 | P00742 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | AKT1 | P31749 | 1/20 | 0.36 |
| ▸ | MYLK | Q15746 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29395301 | 1.00 | HSD11B1 (0.58) | HSD11B1HSD17B1HSD17B2EDNRBEDNRA | |
| SCHEMBL3615780 | 0.95 | HSD11B1 (0.56) | HSD11B1HSD17B1HSD17B2EDNRBEDNRA | |
| SCHEMBL3618840 | 0.95 | HSD11B1 (0.56) | HSD11B1HSD17B1HSD17B2EDNRBEDNRA | |
| SCHEMBL3617080 | 0.91 | HSD11B1 (0.57) | HSD11B1HSD17B1HSD17B2EDNRBEDNRA | |
| SCHEMBL3619392 | 0.88 | HSD11B1 (0.59) | HSD11B1HSD17B1HSD17B2EDNRBEDNRA | |
| SCHEMBL3618053 | 0.87 | HSD11B1 (0.60) | HSD11B1HSD17B1HSD17B2EDNRBEDNRA | |
| SCHEMBL5692990 | 0.86 | HSD11B1 (0.64) | HSD11B1HSD17B1HSD17B2EDNRBEDNRA | |
| Hydrochloric Acid SCHEMBL3615771 | 0.86 | HSD11B1 (0.63) | HSD11B1HSD17B1HSD17B2EDNRBEDNRA | |
| SCHEMBL3612432 | 0.85 | HSD11B1 (0.57) | HSD11B1HSD17B1HSD17B2EDNRBEDNRA | |
| Hydrochloric Acid SCHEMBL3620257 | 0.85 | HSD11B1 (0.65) | HSD11B1HSD17B1HSD17B2EDNRBEDNRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100113435-A1 | INHIBITORS OF 11-BETA-HYDROXY STERIOD DEHYDROGENASE TYPE 1 | BIOVITRUM AB | 2010-05-06 | — | — | US | claimed |
| US-7618961-B2 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | BIOVITRUM AB (SE) | 2009-11-17 | — | — | US | claimed |
| EP-1638553-A1 | NEW USE I | BIOVITRUM AB (SE) | 2006-03-29 | — | — | EP | claimed |
| WO-2004112784-A1 | NEW USE I | BIOVITRUM AB (SE) | 2004-12-29 | — | — | WO | claimed |
| US-20040224996-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | BIOVITRUM AB (SE) | 2004-11-11 | — | — | US | claimed |
| EP-1283831-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | BIOVITRUM AB (SE) | 2003-02-19 | — | — | EP | claimed |
| WO-2001090090-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | BIOVITRUM AB (SE) | 2001-11-29 | — | — | WO | claimed |
| US-10894054-B2 | FXR agonist compositions for combination therapy | INTERCEPT PHARMACEUTICALS, INC. (US) | 2021-01-19 | — | — | US | disclosed |
| WO-2020128529-A1 | COMPOSITIONS AND USES THEREOF | BENEVOLENTAI BIO LIMITED (GB) | 2020-06-25 | — | — | WO | disclosed |
| WO-2020128529-A1 | COMPOSITIONS AND USES THEREOF | BENEVOLENTAI BIO LIMITED (GB) | 2020-06-25 | — | — | WO | disclosed |
| WO-2019186171-A1 | TREATMENT OF SARCOPENIC DISEASES | BENEVOLENTAI BIO LIMITED (GB) | 2019-10-03 | — | — | WO | disclosed |
| US-10039772-B2 | Methods and compositions for treating alcohol use disorders | SANNA PIETRO PAOLO (US) | 2018-08-07 | — | — | US | disclosed |
| US-10039772-B2 | Methods and compositions for treating alcohol use disorders | SANNA PIETRO PAOLO (US) | 2018-08-07 | — | — | US | disclosed |
| EP-1638553-A1 | NEW USE I | BIOVITRUM AB (SE) | 2006-03-29 | — | — | EP | disclosed |
| US-20050186659-A1 | Methods for protein purification | BIOVITRUM AB (SE) | 2005-08-25 | — | — | US | disclosed |
| WO-2005068646-A1 | METHODS FOR THE PROTEIN PRODUCTION AND PURIFICATION OF SOLUBLE RECOMBINANT POLYPEPTIDES | BIOVITRUM AB (SE) | 2005-07-28 | — | — | WO | disclosed |
| WO-2004112784-A1 | NEW USE I | BIOVITRUM AB (SE) | 2004-12-29 | — | — | WO | disclosed |
| US-20040224996-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | BIOVITRUM AB (SE) | 2004-11-11 | — | — | US | disclosed |
| EP-1283831-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | BIOVITRUM AB (SE) | 2003-02-19 | — | — | EP | disclosed |
| WO-2001090090-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | BIOVITRUM AB (SE) | 2001-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10039772-B2 | Methods and compositions for treating alcohol use disorders | HSD3B1, HSD11B1, HSD3B2 | HSD11B1 2/4885HSD17B1 5/4885HSD17B2 6/4885 |
| US-10894054-B2 | FXR agonist compositions for combination therapy | GPR119, FXR1, NR1H4 | HSD11B1 241/4885HSD17B1 245/4885HSD17B2 284/4885 |
| US-20040224996-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | HSD11B1, HSD17B1, HSD11B2 | HSD11B1 1/4885HSD17B1 2/4885HSD17B2 5/4885 |
| US-20100113435-A1 | INHIBITORS OF 11-BETA-HYDROXY STERIOD DEHYDROGENASE TYPE 1 | HSD11B1, HSD17B1, HSD3B1 | HSD11B1 1/4885HSD17B1 2/4885HSD17B2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.